A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia

Trial Profile

A Phase 1 Study of the Deglycosylated Ricin A Chain-containing Combined Anti-CD19 and Anti-CD22 Immunotoxin Combotox in Combination With High-dose Cytarabine in Adult Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Anti CD22 anti CD19 monoclonal antibody toxin conjugate (Primary) ; Cytarabine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
    • 25 Jul 2014 Planned number of patients changed from 20 to 18 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top